

## INTISARI

**ASTUTI N, 2018. ANALISIS KESESUAIAN BIAYA RIIL PADA PASIEN RAWAT INAP PENYAKIT GINJAL KRONIK DENGAN HEMODIALISIS DI RSUD DR. MOEWARDI SURAKARTA DENGAN INA-CBG's TAHUN 2017 – AGUSTUS 2018, TESIS, FAKULTAS FARMASI, UNIVERSITAS SETIA BUDI, SURAKARTA.**

Penderita penyakit ginjal kronik dari tahun ke tahun semakin meningkat dan rata-rata pasien sudah stadium IV sampai V sehingga hampir semua pasien harus melakukan hemodialisis, hal tersebut menjadi masalah besar karena biaya selama perawatan yang mahal, maka dilakukan penelitian analisis biaya. Penelitian ini bertujuan untuk mengetahui rata-rata biaya riil, pengaruh faktor-faktor terhadap biaya riil dan kesesuaian biaya riil dengan tarif INA-CBG's.

Penelitian ini merupakan penelitian observasional dengan menggunakan rancangan penelitian *cross sectional* menurut perspektif rumah sakit. Subyek penelitian adalah pasien penyakit ginjal kronik stadium IV dan V yang dilakukan hemodialisis di RSUD DR. Moewardi periode tahun 2017. Metode pengambilan data dilakukan secara retrospektif dan data yang diambil adalah data kuantitatif. Analisis yang digunakan adalah *Onet sample t-test*.

Berdasarkan hasil penelitian diperoleh kesimpulan pola pengobatan pasien yang paling banyak digunakan adalah golongan antihipertensi dengan obat furosemid sebesar 8,66%, rata-rata biaya riil berdasarkan kelas dan tingkat keparahan kode INA-CBG's N-4-10-I kelas perawatan 1,2,3 sebesar Rp. 7.450.946,50; Rp. 3.412.328,60; Rp. 1.970.663,43. Pada tingkat keparahan kode INA-CBGs N-4-10-II kelas perawatan 1,2,3 sebesar Rp. 10.473.257,00; Rp. 8.620.462,00; Rp. 3.894.940,70. Pada tingkat keparahan kode INA-CBGs N-4-10-III kelas perawatan 1,2,3 sebesar Rp. 15.934.157,94; Rp. 9.517.608,44; Rp. 8.974.199,00. Faktor yang paling berpengaruh adalah LOS (*length of stay*) dengan nilai  $P < 0,05$  (0,000). Hasil uji statistik dengan nilai  $P < 0,05$  (0,000) biaya riil dan biaya INA-CBG's terdapat ketidaksesuaian antara biaya riil dan tarif INA-CBG's.

**Kata kunci : penyakit ginjal kronik, hemodialisis, rawat inap, tarif INA-CBG's, biaya riil.**

## ABSTRACT

**ASTUTI N, 2018. ANALYSIS OF COMPATIBILITY REAL COST OF CHRONIC KIDNEY INPATIENT WITH HEMODIALYSIS IN DR. MOEWARDI REGIONAL PUBLIC HOSPITAL OF SURAKARTA WITH INA-CBG'S IN 2017 - AUGUST, 2018 THESIS, FACULTY OF PHARMACY, SETIA BUDI UNIVERSITY OF SURAKARTA.**

Patients with Chronic Kidney Disease is increasing from year to year and the average patient of Chronic Kidney Disease already in stage IV to V so that almost all patients of stage IV and V should do hemodialysis, it becomes a big problem because the cost during treatment is expensive, then done research of cost analysis. This study was aimed to determine the average of real cost, affect of the factors to real cost and fitness of real cost with INA-CBG's cost.

This research was observational research using *cross sectional* research design according to hospital perspective. The subjects and the objects of this study were inpatient of chronic kidney disease stage IV and stage V who perform hemodialysis in DR. Moewardi Hospital period from January to December 2017. The data taken by retrospectively method and the data was quantitative data. The analysis used was *One sample t-test*.

Based on the result obtained conclusions that the most used treatment of patients was anti-hypertension with furosemide drug of 8.66%, average of real cost based on grade and severity code of INA-CBG's N-4-10-I treatment class 1,2,3 were IDR. 7.450.946,50; IDR. 3.412.328,60; IDR. 1.970.663,43.. On the severity code of INA-CBGs N-4-10-II treatment class 1,2,3 were IDR. 10.473.257,00; IDR. 8.620.462,00; IDR. 3.894.940,70.. On the severity code of INA-CBGs N-4-10-III treatment class 1,2,3 were IDR. 15.934.157,94; IDR. 9.517.608,44; IDR. 8.974.199,00. The most influence factor was LOS (*length of stay*) with P value <0,05 (0,000). Statistical test results with a value of P <0.05 (0,000) real costs and INA-CBG's there is a discrepancy between the real costs and the INA-CBG's cost.

**Key words: Chronic Kidney Disease, Hemodialysis, Inpatient, Tarif INA-CBG's, Analysis real Costs.**